Delving into the Latest Updates on Velimogene aliplasmid with Synapse

Overview

Basic Info

Drug Type

Gene therapy

Synonyms

ALLOVECTIN-7, Allovectin, Velimogene aliplasmid (INN/USAN)

+ [3]

Target

B2M x HLA-B

Mechanism

B2M inhibitors(Beta-2-microglobulin inhibitors), HLA-B inhibitors(major histocompatibility complex, class I, B inhibitors)

Therapeutic Areas

NeoplasmsMouth and Tooth DiseasesOtorhinolaryngologic Diseases+ [2]

Active Indication-

Inactive Indication

Melanoma recurrentMetastatic melanomaSquamous Cell Carcinoma of Head and Neck+ [1]

Originator Organization

Vical, Inc.

Active Organization-

Inactive Organization

Vical, Inc.

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 527925266

Source: *****

RATIONALE: Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells.
PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating patients who have stage III or stage IV melanoma that has not responded to previous treatment.

Start Date01 Aug 1998

Sponsor / Collaborator

Vical, Inc.

100 Clinical Results associated with Velimogene aliplasmid

Login to view more data

100 Translational Medicine associated with Velimogene aliplasmid

Login to view more data

100 Patents (Medical) associated with Velimogene aliplasmid

Login to view more data

22

Literatures (Medical) associated with Velimogene aliplasmid

01 Aug 2017·Melanoma ResearchQ4 · MEDICINE

Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report

Q4 · MEDICINE

Article

Author: Simone M. Goldinger ; Reinhard Dummer ; Lars E. French ; Pascale Kränzlin-Stieger ; Carla Murer

Treatment of melanoma remains a challenge in advanced disease. Recently, the molecular differentiation in BRAF-mutated, NRAS-mutated and c-kit-mutated melanomas led to new treatment strategies. Different trials show that imatinib or nilotinib lead to meaningful responses in c-kit-mutated melanoma patients. There are little published data on sequential inhibition using these two drugs in melanoma. We describe the sequential use of imatinib after nilotinib in a c-kit-mutated melanoma patient, who progressed on interferon, Allovectin, dacarbazine, nilotinib and ipilimumab, and was finally treated with the c-kit inhibitor imatinib. From July 2011 to September 2011, the patient received ipilimumab (four doses with 3 mg/kg). Clinical assessment after immunotherapy showed disease progression. Therefore, a treatment change to imatinib 800 mg daily was made from February 2012 to May 2013. Under this treatment, the patient showed a partial response as per the RECIST criteria. The present lesions continued responding (computed tomography scans: May 2012–March 2013). Unfortunately, in October 2012, new brain metastases developed. Nevertheless, the use of c-kit inhibitors in c-kit-mutated melanoma patients seems to be a promising treatment option. Furthermore, a delayed response to ipilimumab after 6 months could also have led to or supported the partial response in this case. However, when two biologically similar compounds are administered in a melanoma patient and the tumour mass shows progressive disease upon administration of the first agent, an additional progression with no effect may be expected when the second one is used. This case shows, in contrast, that the use of imatinib after progression upon nilotinib can be beneficial.

01 Mar 2015·Current Opinion in OncologyQ3 · MEDICINE

promise and limitation

Q3 · MEDICINE

Review

Author: Agarwala, Sanjiv S

PURPOSE OF REVIEWPatients with unresectable, multiple or advanced locally/regionally metastatic stage IIIB/C or stage IV M1a melanoma have a high risk for recurrence, progression and metastasis. The article reviews treatment advances for this population.RECENT FINDINGSAfter promising phase 2 results with Allovectin-7 (velimogene aliplasmid), overall survival in a phase 3 study was shorter for Allovectin-7 than for dacarbazine/temozolomide (median 18.8 versus 24.1 months).In a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 among 28 patients with advanced melanoma, the primary endpoint of best overall response rate within 24 weeks of first treatment was 32.2% for objective response and 10.7% for complete response.In the phase 3 OPTiM trial of talimogene laherparepvec, the intralesional agent that is furthest along in clinical testing, the primary endpoint of durable response rate was 16% for talimogene laherparepvec and 2% for granulocyte macrophage colony-stimulating factor.In the PV-10 phase 2 trial among 80 patients with stage III-IV melanoma, the overall response rate was 51%, with a 26% complete response rate.SUMMARYDespite advances, many patients will need several lines of therapy. Some will not be eligible for systemic therapy. Their low toxicity, easy administration and likely systemic immune effects make intralesional therapies an attractive option.

01 Oct 2013·Clinical Cancer Research

A Sea Change in Melanoma

Article

Author: Bates, Susan E.

As this issue of Clinical Cancer Research goes to press, Vical, Inc., a pharmaceutical company developing an intralesional gene therapy for melanoma, Allovectin-7, announced its decision to discontinue development following negative results in a phase III trial ([1][1]). This story highlights the

1

News (Medical) associated with Velimogene aliplasmid

05 Dec 2007

·www.biospace.com

John Wayne Cancer Institute: Allovectin-7® May Offer Patients a New Option for Advanced Melanoma

SANTA MONICA, Calif.--(BUSINESS WIRE)--Skin cancer specialists at The John Wayne Cancer Institute at Saint John’s Health Center are recruiting patients into a large Phase 3 study to evaluate the safety and effectiveness of Allovectin-7®, an investigational product for advanced melanoma. If Allovectin-7® is found to be safe and effective in clinical trials, it may offer patients a new option for fighting advanced melanoma (stage 3 or stage 4). Safety and efficacy data from a Phase 2 clinical trial of Allovectin-7® were presented at the 2006 American Society of Clinical Oncology (ASCO) meeting. The ongoing Phase 3 study is designed to determine whether more patients with advanced melanoma respond favorably to Allovectin-7® alone than to current standard chemotherapy alone. To find out whether you or someone you know qualifies for the study, please visit

ASCO

100 Deals associated with Velimogene aliplasmid

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09030	-	-	-

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Squamous Cell Carcinoma of Head and Neck	Phase 3	US	Vical, Inc.	09 Dec 2002
Squamous Cell Carcinoma of the Oropharynx	Phase 3	US	Vical, Inc.	09 Dec 2002
Melanoma recurrent	Phase 3	US	Vical, Inc.	01 Jul 1998
Metastatic melanoma	Phase 3	US	Vical, Inc.	01 Jul 1998

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2012	Phase 2	Metastatic melanoma	127	velimogene aliplasmid (Clinical Benefit (CB))	(oegiupxasy) = leqygpxuqc cwalrznhcr (cvwurknsng, 6.2 - 17.4) View more	-	20 May 2012
ASCO2012	Phase 2	Metastatic melanoma	127	velimogene aliplasmid (Progressive Disease (PD))	(viqtenspxr) = prfzugfins upovqsjuff (eraobqvwji )	-	20 May 2012
ASCO2011	Phase 2/3	Melanoma	-	Allovectin 2 mg	(mwxgtqseex) = mdhppdpsfw hsgtmhblxo (gxakiirxlx ) View more	Positive	20 May 2011
ASCO2005	Phase 2	Metastatic melanoma	133	Allovectin-7	(odvwnivifa) = prlfxofiqr rcrcmkqlic (uicplqtxgq, 8.3 - ongoing) View more	-	01 Jun 2005
ASCO2004	Phase 2	Metastatic melanoma	133	Allovectin-7	(kwrokfwiis) = One Grade 3 adverse event associated with A-7 have been reported vuebrraecs (vaowdfmzhn ) View more	-	15 Jul 2004